Procyclidine is an anticholinergic drug principally used for the treatment of drug-induced parkinsonism, akathisia and acute dystonia, Parkinson's disease, and idiopathic or secondary dystonia. It is a tertiary amine with central antimuscarinic activity that antagonizes muscarinic acetylcholine receptors in the basal ganglia to restore the dopaminergic/cholinergic balance, providing relief of extrapyramidal symptoms; the compound is lipophilic and crosses the blood brain barrier, is well absorbed after oral administration and is also available for parenteral use in some markets. Clinically relevant properties include predictable anticholinergic adverse effects such as dry mouth, blurred vision, constipation, urinary retention and cognitive impairment in susceptible patients, hepatic metabolism with renal excretion of metabolites, and potential interactions with other central nervous system depressants and anticholinergic agents; routine monitoring for response and anticholinergic toxicity is recommended, and use is contraindicated or requires caution in patients with untreated narrow angle glaucoma, significant prostatic hypertrophy with urinary retention, or severe gastrointestinal obstruction.
Parent: Procyclidine
Parent: Procyclidine
Parent: Procyclidine
The procyclidine active pharmaceutical ingredient is typically characterized and controlled by validated chromatographic and spectrometric methods and related substances are maintained within tight limits to ensure safety and efficacy; typical specification ranges used in quality control are individual specified related compounds not greater than 0.1 percent w/w and total impurities not greater than 0.5 percent w/w, with reporting and identification per ICH Q3A thresholds. Known related compounds and degradants include N-desmethyl procyclidine, procyclidine N-oxide, dehydration or dealkylation products and positional isomers that can arise during synthesis or storage, and these are quantified by HPLC with orthogonal confirmation by LC-MS or GC-MS as needed. Residual solvents, heavy metals and water content are controlled according to ICH Q3C and Q3D guidelines and pharmacopeial standards, with residual solvents limited to the applicable ICH class-specific limits and elemental impurities managed within accepted ppm levels.
Procyclidine is used to treat extrapyramidal symptoms including drug-induced parkinsonism, akathisia and acute dystonia, and may be used as adjunctive therapy for Parkinson’s disease and for idiopathic or secondary dystonia to reduce involuntary movements caused by cholinergic overactivity.
No, procyclidine is not an antipsychotic; it is an anticholinergic agent used to manage extrapyramidal side effects that can result from antipsychotic treatments, but it has no antipsychotic efficacy against psychotic symptoms.
Procyclidine is not classified as a classical muscle relaxant; its benefit in dystonia and certain extrapyramidal conditions results from central antimuscarinic effects that reduce abnormal muscle tone and involuntary movements rather than direct peripheral skeletal muscle relaxation.
Procyclidine can cause central nervous system effects including drowsiness and cognitive impairment in some patients, so mild to moderate sedation is possible, particularly when combined with other sedating medications or in elderly individuals.
